Literature DB >> 10419505

Chloroethylclonidine and 2-aminoethyl methanethiosulfonate recognize two different conformations of the human alpha(2A)-adrenergic receptor.

A Marjamäki1, H Frang, M Pihlavisto, A M Hoffrén, T Salminen, M S Johnson, J Kallio, J A Javitch, M Scheinin.   

Abstract

The substituted cysteine-accessibility method and two sulfhydryl-specific reagents, the methane-thiosulfonate derivative 2-aminoethyl methanethiosulfonate (MTSEA) and the alpha(2)-adrenergic receptor (alpha(2)-AR) agonist chloroethylclonidine (CEC), were used to determine the relative accessibility of engineered cysteines in the fifth transmembrane domain of the human alpha(2A)-AR (Halpha2A). The second-order rate constants for the reaction of the receptor with MTSEA and CEC were determined with the wild type Halpha2A (cysteine at position 201) and receptor mutants containing accessible cysteines at other positions within the binding-site crevice (positions 197, 200, and 204). The rate of reaction of CEC was similar to that of MTSEA at residues Cys-197, Cys-201, and Cys-204. The rate of reaction of CEC with Cys-200, however, was more than 5 times that of MTSEA, suggesting that these compounds may interact with two different receptor conformations. MTSEA, having no recognition specificity for the receptor, likely reacts with the predominant inactive receptor conformation (R), whereas the agonist CEC may stabilize and react preferentially with the active receptor conformation (R*). This hypothesis was consistent with three-dimensional receptor-ligand models, which further suggest that alpha(2A)-AR activation may involve the clockwise rotation of transmembrane domain 5.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10419505     DOI: 10.1074/jbc.274.31.21867

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  6 in total

1.  Disparate ligand-mediated Ca(2+) responses by wild-type, mutant Ser(200)Ala and Ser(204)Ala alpha(2A)-adrenoceptor: G(alpha15) fusion proteins: evidence for multiple ligand-activation binding sites.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-08       Impact factor: 8.739

2.  Partial to complete antagonism by putative antagonists at the wild-type alpha(2C)-adrenoceptor based on kinetic analyses of agonist:antagonist interactions.

Authors:  P J Pauwels; F C Colpaert
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

3.  Conserved structural, pharmacological and functional properties among the three human and five zebrafish alpha 2-adrenoceptors.

Authors:  Jori O Ruuskanen; Jonne Laurila; Henri Xhaard; Ville-Veikko Rantanen; Karoliina Vuoriluoto; Siegfried Wurster; Anne Marjamäki; Minna Vainio; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2005-01       Impact factor: 8.739

4.  Involvement of the first transmembrane segment of human α(2) -adrenoceptors in the subtype-selective binding of chlorpromazine, spiperone and spiroxatrine.

Authors:  J M M Laurila; G Wissel; H Xhaard; J O Ruuskanen; M S Johnson; M Scheinin
Journal:  Br J Pharmacol       Date:  2011-11       Impact factor: 8.739

5.  Azi-medetomidine: Synthesis and Characterization of a Novel α2 Adrenergic Photoaffinity Ligand.

Authors:  Andrew R McKinstry-Wu; Kellie A Woll; Thomas T Joseph; Weiming Bu; E Railey White; Natarajan V Bhanu; Benjamin A Garcia; Grace Brannigan; William P Dailey; Roderic G Eckenhoff
Journal:  ACS Chem Neurosci       Date:  2019-11-05       Impact factor: 4.418

6.  Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.

Authors:  Juha M Peltonen; Tommi Nyrönen; Siegfried Wurster; Marjo Pihlavisto; Anna-Marja Hoffrén; Anne Marjamäki; Henri Xhaard; Liisa Kanerva; Juha-Matti Savola; Mark S Johnson; Mika Scheinin
Journal:  Br J Pharmacol       Date:  2003-08-18       Impact factor: 8.739

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.